Table 2.

Clinical, survival and treatment data of EBV + TNK-cell lymphoproliferative disease

No	Ohshima category*	Histo	Sex	Ethnicity	Age (yrs)	Tissue type	GEP	HLH	Treatment	Follow up	OS (mth)
1	A1	P	M	Indonesian	3.4	BM	No	+	HLH -P	Alive	55
2	A1	P	M	Chinese	13.1	BM	No	+	HLH-P, AHCT	Dead (AHCT complications)	48
3	A1	P	M	Vietnamese	24.8	BM	No	+	Chemo	Alive	6
4	A2	P	F	Chinese	5.3	BM	No	+	HLH-P, AHCT	Alive	64
5	A2	P	M	Chinese	1.4	Skin	Yes	+	HLH-P , AHCT	Alive (graft rejection)	95
6	A2	P	F	Indonesian	6.1	BM	No	+	HLH-P	Alive	31
7	A2	P	M	Chinese	16.7	LN	Yes	-	Steroids, AHCT	Dead	14
8	A1 or A2	P	M	Japanese	4	liver	No	+	AHCT	Alive	94.4
9	A1 or A2	P	F	Japanese	19	BM	No	-	AHCT	Alive	9.2
10	A1 or A2	P	F	Japanese	19	BM	No	+	Chemo	Alive	32.5
11	A1 or A2	P	F	Japanese	39	Skin	No	-	Chemo	Dead	21.8
12	A3	M	F	Vietnamese	16.4	BM	No	+	HLH-P	Dead	0.4
13	A3	M	F	Chinese	4.8	BM	No	+	HLH-P	Alive	21
14	B	M	M	Indonesian	13.3	BM	No	+	HLH -P	Dead	0.83
15	B	M	M	Indonesian	20.9	BM	No	+	HLH -P	Dead	2
16	B	M	F	Chinese	9.5	LN	Yes	+	Supportive	Dead	1
17	B	M	M	Chinese	18.7	LN	Yes	+	HLH -P	Dead	1.16
18	B	M	M	Vietnamese	1	BM	No	+	HLH-P	NA	NA
19	B	M	M	Filipino	7.6	BM	No	+	HLH-P	Dead	1
20	B	M	F	Chinese	19.3	BM	No	+	HLH-P	Dead	0.1
21	B	M	F	Japanese	48	BM	No	+	Chemo, AHCT	Dead	2.2
22	A3 or B	M	M	Others	18.3	BM	No	NA	Supportive	Dead	0.7

Abbreviations: M male, F female, Histo histology, P polymorphic, M monomorphic, HLH-P 2004 Histiocytic Lymphohistiocytosis protocol, AHCT Allogeneic hematopoietic cell transplant, + present, − absent, TCR Clonality for TCRG gene, R rearranged, NR not rearranged, NA not available, OS overall survival, LN lymph node, BM bone marrow, Chemo chemotherapy. *Categorization of EBV-associated T/NK LPD in children proposed by Ohshima et al. [13].